Tactica sale
This article was originally published in The Rose Sheet
Executive Summary
Helen of Troy sells its 55% ownership interest in Tactica International depilatory business to brand's current operating management, company announces April 30. Firm had announced plans to evaluate "strategic alternatives" for Tactica in October (1"The Rose Sheet" Oct. 6, 2003, p. 7) In light of the sale, Helen of Troy is revising its fiscal Q4 (ended Feb. 29) and year-end guidance. Fourth quarter net income from core business activities is expected to be approximately $16 mil., with an $8.5 mil.-$9.5 mil. loss attributed to Tactica operations. Consolidated net earnings, which will be announced May 13, are anticipated to be $6.5 mil.-$7.5 mil. Helen of Troy forecasts full-year consolidated net earnings of $59.2 mil.-$60.2 mil. and net income from the core business of $71 mil., with Tactica recording a $10.8 mil.-$11.8 mil. loss...
You may also be interested in...
Helen Of Troy Exploring Options For Tactica Depilatory Business
Helen of Troy is "evaluating strategic alternatives" for its investment in Tactica, the firm's depilatory products business, Chairman, President and CEO Gerald Rubin announced during a second quarter sales and earnings presentation Oct. 2
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.